NeOnc Technologies NTHI 深 滬
等待開盤 09-24 09:30:00 美东时间
3.22
-0.230
-6.67%
華盛通- 最 高3.5207
- 今 開3.44
- 成交量 9.60万股
- 最 低 3.125
- 昨 收 3.45
- 總市值 9.28万
- 52周最高 12.99
- 市盈率 靜 --
- 換手率 0.33%
- 52周最低 2.955
- 委 比 6.10%
- 總股本 2.88万
- 歷史最高 25.00
- 量 比 0.37
- 振 幅 11.47%
- 歷史最低 2.955
- 每 手 1
- 風險率 2.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeOnc Charting New Nasal Route to Treating Brain Cancer
NeOnc Technologies Holdings' NEO100, a nasal spray formulation of perillyl alcohol, shows promise in treating recurrent high-grade glioma, targeting the blood-brain barrier challenge. Phase 2a results demonstrate a 48.9% six-month progression-free survival vs. a 20% benchmark, with median overall survival of 26.09 months. NEO100's intranasal delivery aims to bypass the blood-brain barrier via the olfactory pathway, offering a potential non-invasi...
09-21 12:00
NeOnc Technologies redeems all $6M Series A preferred stock
NeOnc Technologies (NTHI) said on Thursday that it had redeemed all 6,000 outstanding Series A preferred shares for $6M. The redemption was funded with part of the proceeds from the company's $15M reg...
09-17 20:59
NeOnc CEO Boosts Stake After Recent Offering
NeOnc Technologies Holdings, Inc. ( ($NTHI) ) has shared an announcement. On Se...
09-17 18:29
NeOnc Announces Executive Chairman, President And CEO Amir Heshmatpour Purchases Additional 35K Of Company Shares For ~$115,400, At Weighted Average Price Of ~$3.30/Shr
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F. Heshmatpour...
09-16 20:04
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
NeOnc Technologies Holdings (NASDAQ: NTHI) has seen significant insider buying, with CEO Amir F. Heshmatpour purchasing 37,000 shares at $3.6654 each, following a $15 million registered direct offering at $4.20 per share. This purchase, along with other insider investments, highlights confidence in the company's prospects. NeOnc recently reported promising Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma, showing a 48.9% six...
09-14 13:07
NeOnc Technologies Enters $15M Securities Purchase Agreements In At‑The‑Market Offering
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into definitive securities purchase agreements with new and ex...
09-09 20:05
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
BTIG Reiterates Buy on NeOnc Technologies Hldgs, Maintains $15 Price Target
BTIG analyst Thomas Shrader reiterates NeOnc Technologies Hldgs (NASDAQ:NTHI) with a Buy and maintains $15 price target.
09-08 18:01
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
As earnings season ends, investors are turning to updated Quant ratings to see how companies stack up after their latest results. These ratings grade stocks on key metrics like value, growth, profits,...
09-01 22:25
NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger
NeOnc Technologies Holdings reported positive Phase 2a results for NEO100 in recurrent IDH1-mutant glioma, achieving a 48.9% six-month progression-free survival and a median overall survival of 26.09 months. The company plans to request a Type B FDA meeting to discuss a potential registrational pathway. NEO100, an intranasal perillyl alcohol formulation, shows promise in CNS cancer treatment. Additional updates include UAE IND approvals and inter...
08-28 14:07
